<DOC>
	<DOCNO>NCT01610427</DOCNO>
	<brief_summary>The purpose study investigate combine set parameter deem impact quality CMI analyse term proportion viable lymphocytes antiretroviral therapy-na誰ve HIV-1 infected subject .</brief_summary>
	<brief_title>Study Optimize Quality Samples Cell-mediated Immunity ( CMI ) ART-na誰ve HIV-1-infected Subjects</brief_title>
	<detailed_description>This study address respective combine impact ( ) time blood collection peripheral blood mononuclear cell ( PBMC ) processing [ `` time-to-process '' ] ( ii ) timing PBMC rest stimulation [ `` rest -time '' ] .</detailed_description>
	<criteria>All subject must satisfy follow criterion study entry : Subjects Investigator believe comply requirement protocol . Written inform consent obtain subject prior study procedure . A male female include 18 55 year age time enrollment . Confirmed HIV1 infection . ARTna誰ve eligible ART treatment per establish guideline . Subjects must never receive ART HIV diagnosis , include lamivudine use chronic hepatitis B infection . The exception shortterm ART prevention mothertochild transmission ( PMTCT ) must complete least 360 day prior enrollment . Viral load level include 2,000 100,000 copies/mL screening . CD4+ T cell count &gt; 500 cells/mm3 screening . If subject female , must nonchildbearing potential , i.e. , current tubal ligation , hysterectomy , ovariectomy postmenopausal . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test screening , agree continue adequate contraception entire study period . The following criterion check time study entry . If exclusion criterion applies , subject must include study : Infection HIV2 . This include subject dual infection HIV1/HIV2 . Planned use hematotoxic product study period . Planned use investigational nonregistered product study period . Acute chronic , clinically relevant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination , serology and/or medical history screening . Grade 3 grade 4 laboratory abnormality , define Division AIDS ( DAIDS ) grade table , screen . Any condition , opinion Investigator , could compromise subject 's adherence study protocol . Planned administration vaccine foreseen study protocol period start 30 day Sample Collection Visit ( Visit 2 ) . Vaccine administer sample Visit 2 . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>CMI</keyword>
	<keyword>HIV</keyword>
	<keyword>Antiretroviral therapy-na誰ve</keyword>
</DOC>